Drug intelligence / Profile preview

EB1004

Development stage: Unknown
Lead developer: Eden Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

EB1004 is a biosimilar monoclonal antibody being developed by Eden Biologics (formerly JHL Biotech) that targets interleukin-12 (IL-12) and interleukin-23 (IL-23). It is a recombinant, fully human IgG1κ monoclonal antibody designed to match the reference product, ustekinumab (Stelara). By binding to the p40 subunit shared by IL-12 and IL-23, EB1004 prevents these cytokines from binding to their receptors on T-cells, thereby inhibiting the inflammatory signaling pathways involved in autoimmune diseases. It is currently in Phase 1 clinical development for the treatment of plaque psoriasis and Crohn's disease.

Other names: ustekinumab biosimilar

Targets

IL12B (Interleukin-12/23 p40 subunit)

Beyond the preview

Go deeper on EB1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB1004.

Explore the full profile